IBDEI214 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34005,0)
 ;;=N00.2^^154^1722^4
 ;;^UTILITY(U,$J,358.3,34005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34005,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,34005,1,4,0)
 ;;=4^N00.2
 ;;^UTILITY(U,$J,358.3,34005,2)
 ;;=^5015493
 ;;^UTILITY(U,$J,358.3,34006,0)
 ;;=N00.3^^154^1722^5
 ;;^UTILITY(U,$J,358.3,34006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34006,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34006,1,4,0)
 ;;=4^N00.3
 ;;^UTILITY(U,$J,358.3,34006,2)
 ;;=^5015494
 ;;^UTILITY(U,$J,358.3,34007,0)
 ;;=N00.4^^154^1722^3
 ;;^UTILITY(U,$J,358.3,34007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34007,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34007,1,4,0)
 ;;=4^N00.4
 ;;^UTILITY(U,$J,358.3,34007,2)
 ;;=^5015495
 ;;^UTILITY(U,$J,358.3,34008,0)
 ;;=N00.5^^154^1722^6
 ;;^UTILITY(U,$J,358.3,34008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34008,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,34008,1,4,0)
 ;;=4^N00.5
 ;;^UTILITY(U,$J,358.3,34008,2)
 ;;=^5015496
 ;;^UTILITY(U,$J,358.3,34009,0)
 ;;=N00.6^^154^1722^1
 ;;^UTILITY(U,$J,358.3,34009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34009,1,3,0)
 ;;=3^Acute nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,34009,1,4,0)
 ;;=4^N00.6
 ;;^UTILITY(U,$J,358.3,34009,2)
 ;;=^5015497
 ;;^UTILITY(U,$J,358.3,34010,0)
 ;;=N00.7^^154^1722^2
 ;;^UTILITY(U,$J,358.3,34010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34010,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,34010,1,4,0)
 ;;=4^N00.7
 ;;^UTILITY(U,$J,358.3,34010,2)
 ;;=^5015498
 ;;^UTILITY(U,$J,358.3,34011,0)
 ;;=N00.8^^154^1722^9
 ;;^UTILITY(U,$J,358.3,34011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34011,1,3,0)
 ;;=3^Acute nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,34011,1,4,0)
 ;;=4^N00.8
 ;;^UTILITY(U,$J,358.3,34011,2)
 ;;=^5015499
 ;;^UTILITY(U,$J,358.3,34012,0)
 ;;=N00.9^^154^1722^10
 ;;^UTILITY(U,$J,358.3,34012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34012,1,3,0)
 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,34012,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,34012,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,34013,0)
 ;;=N01.0^^154^1722^70
 ;;^UTILITY(U,$J,358.3,34013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34013,1,3,0)
 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,34013,1,4,0)
 ;;=4^N01.0
 ;;^UTILITY(U,$J,358.3,34013,2)
 ;;=^5015501
 ;;^UTILITY(U,$J,358.3,34014,0)
 ;;=N01.1^^154^1722^69
 ;;^UTILITY(U,$J,358.3,34014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34014,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,34014,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,34014,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,34015,0)
 ;;=N01.2^^154^1722^67
 ;;^UTILITY(U,$J,358.3,34015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34015,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,34015,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,34015,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,34016,0)
 ;;=N01.3^^154^1722^65
 ;;^UTILITY(U,$J,358.3,34016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34016,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34016,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,34016,2)
 ;;=^5015504
